Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.69 |
| ▸ | RELA | Q04206 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | ACP1 | P24666 | 1/20 | 0.68 |
| ▸ | NCS1 | P62166 | 1/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4862601 | 0.88 | POLB (0.74) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL29485044 | 0.84 | DYRK1A (0.69) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL6206186 | 0.84 | RAB9A (0.72) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL25938107 | 0.84 | CSNK1D (0.69) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL29485043 | 0.84 | DYRK1A (0.69) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA | |
| Ethylene SCHEMBL8167289 | 0.84 | CSNK1D (0.69) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL29282910 | 0.84 | DYRK1A (0.69) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL7933388 | 0.84 | HDAC3 (0.71) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL4858014 | 0.84 | CSNK1D (0.69) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL25333657 | 0.83 | CSNK1D (0.68) | CSNK1DSMN1; SMN2NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111087363-A | N-heterocyclic substituted-2-bromoacetamide compound for crop bacteriostasis and preparation method thereof | 湖南科技大学 | 2020-05-01 | — | — | CN | claimed |
| CN-111087363-B | N-heterocyclic substituted-2-bromoacetamide compound for crop bacteriostasis and preparation method thereof | 湖南科技大学 | 2022-04-12 | — | — | CN | disclosed |
| CN-111087363-A | N-heterocyclic substituted-2-bromoacetamide compound for crop bacteriostasis and preparation method thereof | 湖南科技大学 | 2020-05-01 | — | — | CN | disclosed |
| WO-2007045962-A2 | NOVEL HDAC INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045962-A2 | NOVEL HDAC INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088043-A1 | Novel HDAC inhibitors | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-04-19 | — | — | US | disclosed |
| US-20070088043-A1 | Novel HDAC inhibitors | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-04-19 | — | — | US | disclosed |
| US-20070088043-A1 | Novel HDAC inhibitors | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-04-19 | — | — | US | disclosed |
| US-6991902-B2 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6893815-B1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-5922872-A | BACTERICIDES AND DRUGS | ISIS PHARMACEUTICALS, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1999000669-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
| US-5817489-A | BACTERICIDES, OR CHEMICAL INTERMEDIATES THEREOF; DRUG LIBRARIES | ISIS PHARMACEUTICALS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5798360-A | ANTIBACTERIAL AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| US-5780241-A | ALTERING ELECTROCHEMICAL PROPERTIES BY DECYCLIZATION | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998020349-A1 | COMPLEX CHEMICAL LIBRARIES | ISIS PHARMACEUTICALS, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| US-5731438-A | BACTERICIDES; DRUGS | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1998006671-A1 | METHODS FOR REMOVING UNREACTED ELECTROPHILES FROM A REACTION MIXTURE | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1998005332-A1 | NOVEL HETEROCYCLE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| US-5632898-A | SCAVINGING WITH A WATER-SOLUBLE NUCLEOPHILE COMPRISING AMINO-, HYDROXY- OR MERCAPTO-CONTAINING SULFONATES, CARBOXYLATES OR PHOSPHONATES FOLLOWED BY SEPARATION | ISIS PHARMACEUTICALS, INC. (US) | 1997-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088043-A1 | Novel HDAC inhibitors | HDAC1, HDAC11, HDAC5 | CSNK1D 85/4885SMN1; SMN2 3872/4885NFKB1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.